A. Jeanson

627 total citations
13 papers, 458 citations indexed

About

A. Jeanson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, A. Jeanson has authored 13 papers receiving a total of 458 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in A. Jeanson's work include Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Research Studies (4 papers). A. Jeanson is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Research Studies (4 papers). A. Jeanson collaborates with scholars based in France, Australia and Austria. A. Jeanson's co-authors include Fabrice Barlési, Pascale Tomasini, Laurent Greillier, M. Grangeon, Céline Mascaux, M. Souquet-Bressand, Mohamed Boucékine, S. Chaléat, P Borgeat and Pierré Sirois and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Thoracic Oncology.

In The Last Decade

A. Jeanson

12 papers receiving 452 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Jeanson France 6 320 229 80 79 58 13 458
Tomoyuki Miyazawa Japan 10 90 0.3× 169 0.7× 56 0.7× 56 0.7× 53 0.9× 31 311
Sneẑana Šušnjar Serbia 10 144 0.5× 77 0.3× 94 1.2× 22 0.3× 40 0.7× 35 330
Karen Briscoe Australia 10 275 0.9× 212 0.9× 127 1.6× 62 0.8× 7 0.1× 21 557
Brooke Ancrile United States 3 224 0.7× 47 0.2× 166 2.1× 116 1.5× 58 1.0× 7 399
Kate Young United Kingdom 11 240 0.8× 115 0.5× 92 1.1× 40 0.5× 14 0.2× 30 365
Konstantinos Rounis Greece 11 228 0.7× 100 0.4× 82 1.0× 42 0.5× 40 0.7× 24 341
Zuzana Pernicová Czechia 11 146 0.5× 91 0.4× 202 2.5× 35 0.4× 32 0.6× 12 376
M. Della Giulia Italy 6 193 0.6× 92 0.4× 46 0.6× 38 0.5× 28 0.5× 12 308
Kuo-Pao Lai Taiwan 6 158 0.5× 240 1.0× 227 2.8× 80 1.0× 11 0.2× 6 499
Tsuyoshi Kuroda Japan 6 195 0.6× 59 0.3× 175 2.2× 90 1.1× 15 0.3× 10 368

Countries citing papers authored by A. Jeanson

Since Specialization
Citations

This map shows the geographic impact of A. Jeanson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Jeanson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Jeanson more than expected).

Fields of papers citing papers by A. Jeanson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Jeanson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Jeanson. The network helps show where A. Jeanson may publish in the future.

Co-authorship network of co-authors of A. Jeanson

This figure shows the co-authorship network connecting the top 25 collaborators of A. Jeanson. A scholar is included among the top collaborators of A. Jeanson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Jeanson. A. Jeanson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
3.
Malissen, Nausicaa, Nicolás André, A. Jeanson, et al.. (2022). Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer. Current Oncology. 29(3). 1902–1918. 3 indexed citations
4.
Girard, Nicolas, Martin Wermke, Fabrice Barlési, et al.. (2021). Phase Ib study of BI 836880 (VEGF/Ang2 nanobody) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with solid tumors.. Journal of Clinical Oncology. 39(15_suppl). 2579–2579. 4 indexed citations
5.
Girard, N., Martin Wermke, Evgeny Ledin, et al.. (2021). 532P Phase Ib study evaluating BI 836880 (VEGF/Ang2 nanobody) in combination with ezabenlimab (BI 754091; anti-PD-1 antibody) in patients with solid tumours. Annals of Oncology. 32. S597–S597. 1 indexed citations
6.
Pasquier, Florence, Marc Lecuit, Sophie Broutin, et al.. (2020). Ivosidenib to treat adult patients with relapsed or refractoryacute myeloid leukemia. Drugs of today. 56(1). 21–21. 5 indexed citations
7.
Tomasini, Pascale, et al.. (2019). First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer. Translational Cancer Research. 8(7). 2514–2516. 5 indexed citations
8.
Jeanson, A., Pascale Tomasini, M. Souquet-Bressand, et al.. (2019). Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 14(6). 1095–1101. 171 indexed citations
9.
Jeanson, A., et al.. (2018). Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer. Expert Review of Anticancer Therapy. 19(1). 11–17. 7 indexed citations
10.
Grangeon, M., Pascale Tomasini, S. Chaléat, et al.. (2018). Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer. Clinical Lung Cancer. 20(3). 201–207. 159 indexed citations
11.
Jeanson, A. & Fabrice Barlési. (2017). MEDI 4736 (durvalumab) in non-small cell lung cancer. Expert Opinion on Biological Therapy. 17(10). 1317–1323. 9 indexed citations
12.
Sirois, Pierré, P Borgeat, & A. Jeanson. (1981). Comparative effects of leukotriene B4, prostaglandins I2 and E2, 6-keto-PGF1α, thromboxane B2 and histamine on selected smooth muscle preparations. Journal of Pharmacy and Pharmacology. 33(1). 466–468. 23 indexed citations
13.
Sirois, Pierré, et al.. (1980). The action of leukotriene B4 (LTB4) on the lung. Prostaglandins and Medicine. 5(6). 429–444. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tomoyuki Miyazawa Breakdown of academic impact, for papers by Sneẑana Šušnjar Breakdown of academic impact, for papers by Karen Briscoe Breakdown of academic impact, for papers by Brooke Ancrile Breakdown of academic impact, for papers by Kate Young Breakdown of academic impact, for papers by Konstantinos Rounis Breakdown of academic impact, for papers by Zuzana Pernicová Breakdown of academic impact, for papers by M. Della Giulia Breakdown of academic impact, for papers by Kuo-Pao Lai Breakdown of academic impact, for papers by Tsuyoshi Kuroda
Rankless by CCL
2026